These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1425621

  • 1. Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis.
    Dicato MA, Freeman AJ.
    Eur J Anaesthesiol Suppl; 1992 Nov; 6():19-24. PubMed ID: 1425621
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM.
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [Abstract] [Full Text] [Related]

  • 6. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A, Ratanatharathorn V, Sinlarat P, Chindavijak K, Lousoontornsiri W, Chakrapee-Sirisuk S, Srimuninimit V.
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [Abstract] [Full Text] [Related]

  • 7. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Apr; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 8. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL.
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [Abstract] [Full Text] [Related]

  • 9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
    Hainsworth JD, Hesketh PJ.
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
    [Abstract] [Full Text] [Related]

  • 13. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C, Ferencz T, Koós R, Schuler D, Borsi J.
    Orv Hetil; 1993 Jun 20; 134(25):1363-7. PubMed ID: 8332356
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S, Chareoniam V, Isariyodom P, Sungsab D.
    J Med Assoc Thai; 2001 Jul 20; 84(7):966-72. PubMed ID: 11759977
    [Abstract] [Full Text] [Related]

  • 16. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 20; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD.
    Semin Surg Oncol; 1993 Feb 20; 9(3):279-84. PubMed ID: 8516617
    [Abstract] [Full Text] [Related]

  • 20. [Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
    Nishida T, Yakushiji M, Ohizumi K, Noda S, Rikimaru T, Matsuoka K.
    Gan To Kagaku Ryoho; 2002 Jan 20; 29(1):81-7. PubMed ID: 11816483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.